Companion Animal Arthritis Market Size To Hit USD 125.58 Billion By 2032, Driven By Surge In Pet Ownership And Veterinary Innovations SNS Insider

(MENAFN- GlobeNewsWire - Nasdaq) Increasing arthritis prevalence among aging pets, growing adoption of biologics, and demand for alternative therapies are reshaping the global companion animal arthritis landscape.

Austin, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider , the Companion Animal Arthritis Market size was valued at USD 66.8 billion in 2023 and is projected to reach USD 125.58 billion by 2032, growing at a CAGR of 7.28% over 2024-2032. This growth is primarily driven by the increasing humanization of pets, a rising pet population (particularly aging animals), and advancements in treatment options like biologics.

Get a Sample Report of Companion Animal Arthritis Market:

Increasing Pet Ownership and Humanization of Pets Augment Market Expansion Globally

The need for arthritis treatment in companion animals is significantly driven by the growing trend of pet adoption and the increasing humanization of pets. According to the most recent data, the percentage of American homes with pets has increased from 56% to 66%. Millennials, who account for more pet owners than any other generation and 33% of all pet owners, are to blame for this rise. This trend of humanization is further supported by the strong bonds that pet owners have with their animals.

High Costs of Advanced Arthritis Treatments to Drive Market Growth Globally

One of the main barriers to the companion animal arthritis market is the high expense of arthritis drugs and therapies. Pets with arthritis typically require permanent or long-term therapy, which can be costly for pet owners. Prescription pharmaceuticals called nonsteroidal anti-inflammatory drugs (NSAIDs) are used to relieve pain and inflammation, but they can be costly to take over time. The list of expensive harbingers is further expanded by expensive progressive therapies like platelet-rich plasma (PRP) injections and stem cell therapy.
Major Players Analysis Listed in the Companion Animal Arthritis Market Report are

• Zoetis Inc.
• Elanco Animal Health Incorporated
• Boehringer Ingelheim International GmbH
• Merck Animal Health (MSD Animal Health)
• Virbac S.A.
• Ceva Santé Animale
• Vetoquinol S.A.
• Dechra Pharmaceuticals PLC
• Norbrook Laboratories Ltd.
• Aratana Therapeutics Inc.
• Chanelle Pharma Group
• K-Laser USA
• Assisi Animal Health
• Nutramax Laboratories Inc.
• Hill's Pet Nutrition Inc.
• Nestlé Purina PetCare Company
• Royal Canin
• Mars Petcare
• PetMed Express Inc.
• NexGen Pharmaceuticals.

Companion Animal Arthritis Market Report Scope

Report Attributes	Details
Market Size in 2023	USD 3.4 Billion
Market Size by 2032	USD 6.31 Billion
CAGR	CAGR of 7.14% From 2024 to 2032
Base Year	2023
Forecast Period	2024-2032
Historical Data	2020-2022
Key Segments	. By Animal Type (Cats, Dogs, Others) . By Treatment (Medication {Monoclonal Antibodies, NSAIDs, Others Medications}, Supplements, Other Treatment) . By Indication (Osteoarthritis, Other Arthritis) . By Distribution Channel (Veterinary Hospitals & Clinics, Online Stores, Retail Pharmacies, Others)
Regional Analysis/Coverage	North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America).

For a Personalized Briefing with Our Industry Analysts, Connect Now:

Segmentation Analysis:

By Animal Type

In 2023, the dogs segment accounted for more than 59% of the worldwide companion animal arthritis market share. The overwhelming prevalence of osteoarthritis in dogs, which is often associated with factors, such as age and obesity, may explain this dominance.

By Treatment

In 2023, the medication segment accounted for the highest revenue share of over 54.0%. This growth is primarily driven by the success of drugs, such as NSAIDs and monoclonal antibodies in controlling arthritis symptoms in pets. The medication segment benefits from ongoing research and development in veterinary pharmaceuticals, which continues to enhance treatment options for companion animals.

By Distribution Channel

The veterinary hospitals and clinics segment accounted for the highest revenue share of 35% in 2023. The reason for this dominance is the key method these facilities play in diagnosing and treating arthritis in pets. Additionally, the expertise and trust surrounding veterinary professionals in these types of settings make them favored options for pet owners.

By Indication

The osteoarthritis segment accounted for the largest market share, about 76% of the total revenue in 2023. Arthritis Osteoarthritis is the most common type of arthritis in pets, especially in older dogs and cats. The dominance of osteoarthritis in the market is also driven by the availability of effective treatments and the ongoing research into new therapeutic options, which continue to improve outcomes for affected pets.

Regional Insights:

The largest region in this market is North America, which accounted for 35% of the total market in 2023. The U.S., in particular, dominates the worldwide market, focusing on pet health and the use of advanced diagnostic tools and treatments, including biologic therapies and regenerative medicine.

The fastest-growing market is anticipated to be in the Asia Pacific region on account of the growing pet population and health awareness in countries, such as China and India. Disposable income is increasing in these emerging markets, and veterinarians are also in demand, along with veterinary medicines and treatments for arthritis.

Purchase Single User PDF of Companion Animal Arthritis Market Report (20% Discount):

Recent Developments:

• In January 2024, The U.S. Department of Agriculture announced initiatives to enhance veterinary care infrastructure, which is expected to boost the companion animal arthritis market by improving access to advanced treatments.
• In August 2024, The European Union launched a program to promote animal welfare, including better healthcare services for pets, which could further drive the demand for arthritis treatments.

Exclusive Sections of the Report (The USPs):

• PRESCRIPTION TRENDS ANALYSIS – helps you understand regional variations in the adoption of NSAIDs, corticosteroids, and biologics for companion animal arthritis treatment, highlighting evolving therapeutic preferences.
• DRUG PRODUCTION & UTILIZATION RATES – helps you assess manufacturing output, dosage frequency, and usage growth patterns from 2020–2032, providing insights into supply-demand balance and market scalability.
• HEALTHCARE EXPENDITURE METRICS – helps you analyze veterinary healthcare spending trends across regions and forecast how economic and pet ownership factors influence arthritis treatment affordability.
• ALTERNATIVE THERAPY ADOPTION INDEX – helps you track the growing use of nutraceuticals, physiotherapy, laser therapy, and regenerative medicine as complementary or substitute treatments in animal arthritis care.
• TECHNOLOGICAL ADVANCEMENT RATE – helps you uncover innovation trends in diagnostic imaging, wearables for joint monitoring, and next-generation biologics that enhance arthritis management and animal mobility.
• COMPETITIVE LANDSCAPE INSIGHTS – helps you evaluate leading veterinary pharmaceutical firms and emerging biotech players based on their R&D investments, product pipelines, and regional market expansion strategies.

Access Complete Report Details of Companion Animal Arthritis Market Analysis & Outlook:

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email:...

MENAFN12122025004107003653ID1110472423